Jim Greenwood, BIO

Jim Green­wood set to de­part from BIO af­ter US elec­tions — vows to en­sure law­mak­ers don't 'kill in­no­va­tion'

The her­culean US drug lob­by is los­ing one of its flag­bear­ers: BIO CEO Jim Green­wood.

For more than 14 years Green­wood has led BIO, which has tripled in size un­der his reign and re­brand­ed it­self as the Biotech­nol­o­gy In­no­va­tion (pre­vi­ous­ly In­dus­try) Or­ga­ni­za­tion. He is set to de­part af­ter the US elec­tions next year, and will help tran­si­tion a new leader to rep­re­sent the biotech in­dus­try and “de­fend in­no­va­tion from do­mes­tic po­lit­i­cal at­tacks.”

The an­nounced ex­it comes at a ten­u­ous pe­ri­od for the US bio­phar­ma, which is un­der fire for drug price hikes and is fac­ing in­ten­si­fy­ing scruti­ny by politi­cians, pol­i­cy­mak­ers and pa­tients. The in­dus­try’s rep­u­ta­tion has gone from bad to worse to rock bot­tom, as a slew of scan­dals — from the opi­oid cri­sis to the prices of pre­scrip­tion drugs — take their toll.

BIO, which has an $85 mil­lion op­er­at­ing bud­get and al­so rep­re­sents biotech­nol­o­gy ef­forts with­in agri­cul­ture and en­er­gy, did not dis­close the rea­son be­hind Green­wood’s de­par­ture.

“All of us at BIO will con­tin­ue to de­pend on his thought­ful stew­ard­ship for the next 15 months as we fight short-sight­ed at­tempts to drain cap­i­tal from our sec­tor and cur­tail the in­tel­lec­tu­al prop­er­ty rights of in­no­va­tors,” re­cent­ly ap­point­ed BIO chair­man Je­re­my Levin not­ed in a state­ment.

Green­wood, who once served as a mem­ber of the GOP bloc called the Tues­day Group, emerged as BIO’s sec­ond-ever leader in 2005, suc­ceed­ing found­ing Pres­i­dent Carl Feld­baum — af­ter rep­re­sent­ing a Penn­syl­va­nia dis­trict in the US House of Rep­re­sen­ta­tives.

In Con­gress, Green­wood served as a se­nior mem­ber of the House En­er­gy and Com­merce Com­mit­tee over­see­ing health care pol­i­cy — help­ing ef­forts to mod­ern­ize the FDA, pass the Medicare Part D pre­scrip­tion drug ben­e­fit for se­niors, and lift the ban on em­bry­on­ic stem-cell re­search (al­though the Trump ad­min­is­tra­tion has re­cent­ly lim­it­ed that re­search by abort­ing ac­cess for NIH sci­en­tists), BIO said.

Akin to its in­flu­en­tial lob­by­ing coun­ter­part PhRMA, the 68-year-old Green­wood has en­trenched BIO’s po­si­tion in Con­gress. He led in­dus­try ne­go­ti­a­tions with Con­gress re­lat­ed to pa­tient-cen­tered drug de­vel­op­ment, pro­mot­ed the biosim­i­lars in­dus­try and en­list­ed the en­dorse­ment of Sen­a­tor Ted Kennedy (D-MA) and Or­rin Hatch (R-UT) for the in­dus­try.

“This is a crit­i­cal mo­ment for our in­dus­try as our com­pa­nies take a beat­ing in the court of pub­lic opin­ion,” Green­wood said in a strong­ly-word­ed state­ment. “I will con­tin­ue my full-throat­ed ad­vo­ca­cy to en­sure our elect­ed of­fi­cials do not kill in­no­va­tion in a pop­ulist furor and pre­vent our sci­en­tists from de­liv­er­ing a new gen­er­a­tion of ge­nom­ic cures.”

Green­wood’s im­pend­ing de­par­ture was first re­port­ed by Sarah Kar­lin-Smith at Politi­co.

Tal Zaks, Moderna CMO (Moderna via YouTube)

UP­DAT­ED: NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions re­main to be an­swered

The NIAID and Moderna have spelled out positive Phase I safety and efficacy data for their Covid-19 vaccine mRNA-1273 — highlighting the first full, clear sketch of evidence that back-to-back jabs at the dose selected for Phase III routinely produced a swarm of antibodies to the virus that exceeded levels seen in convalescent patients — typically in multiples indicating a protective response.

Moderna execs say plainly that this first stage of research produced exactly the kind of efficacy they hoped to see in humans, with a manageable safety profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

Modality Solutions is an ISO:9001-registered biopharmaceutical cold chain engineering firm with unique transport simulation capabilities that support accelerated regulatory approval for biologics and advanced therapeutic medicinal products (ATMP). Our expertise combines traditional validation engineering approaches with regulatory knowledge into a methodology tailored for the life sciences industry. We provide insight and execution for the challenges faced in your cold chain logistics network.

Source: Shutterstock

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for End­points' spe­cial re­port

One of the many inequalities the pandemic has laid bare is the gender imbalance in biomedical research. A paper examining Covid-19 research authorship wondered out loud: Where are the women?

It’s a question that echoes beyond our current times. In the biopharma world, not only are women under-represented in R&D roles (particularly at higher levels), their achievements and talents could also be undermined by stereotypes and norms of leadership styles. The problem is even more dire for women of color.

Jeff Albers, Blueprint CEO

Di­ag­nos­tic champ Roche buys its way in­to the RET ti­tle fight with Eli Lil­ly, pay­ing $775M in cash to Blue­print

When Roche spelled out its original $1 billion deal — $45 million of that upfront — with Blueprint to discover targeted therapies against immunokinases, the biotech partner’s RET program was still preclinical. Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game.

Roche gains rights to co-develop and co-commercialize the drug, with sole marketing responsibility for places outside the US and China (where CStone has staked its claim).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Mene Pangalos, AstraZeneca R&D chief (AstraZeneca via YouTube)

A day af­ter Mod­er­na vac­cine re­sults, ru­mors swirl of pend­ing As­traZeneca da­ta

A day after Moderna and the NIH published much-anticipated data from their Phase I Covid-19 vaccine trial, attention is turning to AstraZeneca which, according to a UK report, is expected to publish its own early data tomorrow.

ITV’s Robert Peston reported that AstraZeneca will publish the Phase I data in The Lancet. 

AstraZeneca and Moderna represent the two most ambitious Covid-19 vaccine efforts, having set the quickest timelines for approval (though they were recently joined in that regard by the Pfizer-BioNTech partnership) and some of the loftiest goals in total doses. Yet there is even less known about AstraZeneca’s vaccine’s effect on humans than there was about Moderna’s before yesterday. Although, in a controversial move, Moderna released some statistics from its Phase I in May, AstraZeneca has yet to say anything about what it saw in its Phase I trial — a move consistent with the scientific convention to withhold data until it can be published in a peer-reviewed journal.

Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)

‘Plan­ning to vac­ci­nate every­one in the US,’ Mod­er­na out­lines ef­forts to sup­ply their Covid-19 vac­cine as man­u­fac­tur­ing ramps up ahead of PhI­II

Twelve days from the planned start of their Phase III pivotal trial, the executive crew at Moderna has set up the manufacturing base needed to begin production of the first 500,000 doses of their Covid-19 vaccine with plans to feed it into a global supply chain. But the initial batches will likely be ready in the US first, where company CEO Stéphane Bancel plans to be able to vaccinate everyone.

“We have started making commercial product at-risk, and will continue to do so every day and every week of the month,” Bancel told analysts during their morning call on the Phase I data just published in the New England Journal of Medicine.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Vac­cine by end of 2020? Ken Fra­zier warns hype do­ing 'grave dis­ser­vice'

When it comes to setting expectations about a Covid-19 vaccine, Ken Frazier does not mince words.

Over a month after first casting doubts on the aggressive 12- to 18-month timeframe championed by the US government and his biopharma peers, the Merck CEO again cautioned against any hype around a quick vaccine approval.

In a wide-ranging interview with Harvard Business School professor Tsedal Neeley that touched other big topics such as race, Frazier emphasized that vaccines take a long time to develop. He would know: Out of the seven new vaccines introduced around the world in the past 25 years, four came from Merck.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Moderna CEO (Andrew Harnik/AP Images)

A top an­a­lyst turns the spot­light on Mod­er­na, fu­el­ing a fast-and-fu­ri­ous Street race over the fu­ture of mR­NA

Bioregnum Opinion Column by John Carroll

Four months ago, one of the favorite talking points on the biopharma social media wave length was whether Moderna shares $MRNA were priced right or were wildly inflated.

After all, said the naysayers, the company had never actually pushed a treatment to an approval. Did messenger RNA really work, coding cells to make a drug or a vaccine? And how about all that chatter about how ‘secretive’ they are, or were?

Now, as CEO Stéphane Bancel and the top execs push the company to the forefront of a frantic race to develop the first vaccine to fight against the reignited wildfire spread of Covid-19, all those questions have been magnified — along with the stock price.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ludwig Hantson, Alexion CEO

Why pay $4B for a steady di­et of dis­ap­point­ment? Porges turns thumbs down on Alex­ion’s M&A strat­e­gy, of­fers some point­ers

When Alexion announced recently that it was paying $1.4 billion to bag Portola and its underperforming Factor Xa inhibitor reversal agent, you could hear the head-scratching going on around virtual Wall Street.

Why was Alexion going down the discount lane for new products? And why something like this? Analysts have been urging Alexion to get serious about M&A for years if it was serious about diversifying the company beyond Soliris and its successor drug. But this wasn’t the kind of heavy-impact deal they were looking for.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.